Invention Grant
- Patent Title: Use of isovalerylspiramycins as anti-cancer agents to inhibit metastasis
-
Application No.: US16816068Application Date: 2020-03-11
-
Publication No.: US11351185B2Publication Date: 2022-06-07
- Inventor: Enhong Jiang , Zhengping Zhuang , Jing Cui
- Applicant: ASCLEA CORPORATION , THE UNITED STATES OF AMERICA, as represented by the Secretary, Dept. of Health and Human Svcs.
- Applicant Address: US NV Las Vegas; US MD Bethesda
- Assignee: ASCLEA CORPORATION,THE UNITED STATES OF AMERICA, as represented by the Secretary, Dept. of Health and Human Svcs.
- Current Assignee: ASCLEA CORPORATION,THE UNITED STATES OF AMERICA, as represented by the Secretary, Dept. of Health and Human Svcs.
- Current Assignee Address: US NV Las Vegas; US MD Bethesda
- Agency: Buchanan Ingersoll & Rooney PC
- Main IPC: A61K31/7048
- IPC: A61K31/7048 ; A61P35/04
Abstract:
A pharmaceutical composition containing any one or more of 4″-O-isolvalerylspiramycin I, II and III counters tumorigenesis and reduces or prevents metastasis by inhibiting selenoprotein H to trigger genomic instability and cell-cycle arrest in cancer cells.
Public/Granted literature
- US20210283159A1 USE OF ISOVALERYLSPIRAMYCINS AS ANTI-CANCER AGENTS TO INHIBIT METASTASIS Public/Granted day:2021-09-16
Information query
